Laurus Labs PAT at Rs 201.90 cr. in Q2FY21
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
The NFI is published to promote the rational use of medicines in the country.
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
Acute therapies continue to report strong growth compared to chronic ones.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
The youngest child in India to survive ECMO after undergoing bone marrow transplant for a rare disease
Subscribe To Our Newsletter & Stay Updated